Fig. 5

Immunolabelling for GFAP and collagen IV at 29 days after stroke. A The low power image in the upper panel shows the typical pattern of GFAP labelling, with increases extending more than 1 mm into the grey matter surrounding the infarct. Prominent increases were seen on the rim of the infarct, in grey matter at the base of the infarct and in underlying white matter. The rectangles in this image identify the regions shown in the lower images. The rectangles in the lower images show the tissue that was analyzed. The narrow band of increased immunolabelling above the rectangles corresponds to the developing glial scar. B Effect of olomoucine treatment on the area fraction of GFAP immunolabelling. Olomoucine treatment did not significantly affect the area fraction of GFAP labelling in either hemisphere. There was a marked effect of distance from the lesion on immunolabelling in peri-infarct tissue (p < 0.01) and also a small but significant effect of sampling location in the contralateral cortex (p < 0.01). C Collagen IV immunolabelling. The rectangles delineate the regions in which area fraction of immunolabelling was assessed. D Effect of olomoucine treatment on the area fraction of collagen IV immunolabelling. There was a significant effect of distance from the lesion on immunolabelling in peri-infarct tissue (p < 0.01) but no significant differences in equivalent contralateral tissue. The area fraction of immunolabelling was not significantly affected by olomoucine treatment in either hemisphere. The scale bars in A and C = 200 μm. Results in B and D are shown as mean ± SD (n = 6 per group) and were analyzed using two-way analysis of variance. ##p < 0.01 for the effect of distance from the infarct or of location in the contralateral cortex